Table 1.
Baseline Demographics of SAILS subjects
| Clinical Characteristic | Placebo (343 subjects) | Statin (340 subjects) | Excluded (62 subjects) |
|---|---|---|---|
| Age (years) | 56 (43, 65) | 54 (41, 67) | 53 (43, 65) |
| Gender (% female) | 173 (50%) | 175 (52%) | 32 (52%) |
| White Race | 272 (79%) | 267 (79%) | 51 (82%) |
| APACHE III Score | 92 (76, 115) | 91 (71, 109) | 86 (74, 110) |
| Shock at baseline | 154 (50%) | 155 (51%) | 30 (55%) |
| P:F<200 mmHg | 229 (73%) | 240 (76%) | 41 (71%) |
| Malignancy1 | 45 (13%) | 38 (11%) | 6 (10%) |
| IV or po steroids≥ 20mg | 86 (28%) | 76 (25%) | 18 (32%) |
| AKI | 166 (51%) | 162 (51%) | 27 (48%) |
| Chronic Dialysis | 9 (3%) | 4 (1%) | 2 (3%) |
| ESLD | 17 (5%) | 17 (5%) | 4 (7%) |
| Baseline IL-18 Level (pg/ml) | 557 (412, 736) | 541 (374, 782) | N/A |
Values as N(%) or Median (IQR).
1
Malignancy= lymphoma, leukemia, or metastatic cancer